Precision active pharmaceutical ingredients are the goal

被引:0
|
作者
Miller, Andrew D. [1 ,2 ]
机构
[1] Kings Coll London, Inst Pharmaceut Sci, Franklin Wilkins Bldg,Waterloo Campus, London SE1 9NH, England
[2] KP Therapeut Ltd, 86 Deansgate, Manchester M3 2ER, Lancs, England
关键词
antisense peptides; chemical biology; chemistry of stress; complementary peptides; diadenosine polyphosphates; dinucleoside polyphosphates; molecular chaperones; precision active pharmaceutical ingredients; precision medicine; synthetic biology; thioether fatty acids; TRANSFER-RNA SYNTHETASE; MITOCHONDRIAL MALATE-DEHYDROGENASE; CHAPERONIN; 60; GROEL; PROTEIN; 47; HSP47; ESCHERICHIA-COLI; DIADENOSINE; 5'; 5'''-P-1; P-4-TETRAPHOSPHATE; CPN60; DINUCLEOSIDE POLYPHOSPHATES; CYTOKINE INTERLEUKIN-1; MOLECULAR CHAPERONES;
D O I
10.4155/fmc-2016-0046
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Understanding and exploiting molecular mechanisms in biology is central to chemical biology. Chemical biology studies of biological macromolecules are now in a perfect continuum with molecular level and nanomolecular level mechanistic studies involving whole organisms. The potential opportunity presented by such studies is the design and creation of genuine precision active pharmaceutical ingredients (APIs; including DNA, siRNA, smaller-molecule bioactives) that demonstrate exceptional levels of disease target-specificity and selectivity. This article covers the best of my personal and collaborative academic research work using an organic chemistry and chemical biology approach towards understanding biological molecular recognition processes, work that appears to be leading to the generation of novel precision APIs with genuine potential for the treatments of major chronic diseases that afflict globally.
引用
收藏
页码:1209 / 1238
页数:30
相关论文
共 50 条
  • [41] Enhancing the stability of active pharmaceutical ingredients by the cocrystal strategy
    Liu, Liyu
    Wang, Jian-Rong
    Mei, Xuefeng
    CRYSTENGCOMM, 2022, 24 (11) : 2002 - 2022
  • [42] Principles for Effective Regulatory Active Pharmaceutical Ingredients Policy
    Arthur C. Fabian
    Drug information journal : DIJ / Drug Information Association, 1999, 33 (3): : 747 - 753
  • [44] Improving tabletiblity of active pharmaceutical ingredients through cocrystallization
    Bhattacharya, Biswajit
    Reddy, Chilla Malla
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2017, 73 : C213 - C213
  • [45] An Approach to the Commercial Production of Highly Active Pharmaceutical Ingredients
    Beyeler, Andreas
    Wilhelm, Roland
    Brodbeck, Bernd
    CHIMIA, 2016, 70 (09) : 596 - 603
  • [46] Principles for effective regulatory active pharmaceutical ingredients policy
    Fabian, AC
    DRUG INFORMATION JOURNAL, 1999, 33 (03): : 747 - 753
  • [47] An automated workstation for forced degradation of active pharmaceutical ingredients
    Sims, JL
    Roberts, JK
    Bateman, AG
    Carreira, JA
    Hardy, MJ
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2002, 91 (03) : 884 - 892
  • [48] What is the "typical" particle shape of active pharmaceutical ingredients?
    Yu, Weili
    Liao, Lingzhi
    Bharadwaj, Rahul
    Hancock, Bruno C.
    POWDER TECHNOLOGY, 2017, 313 : 1 - 8
  • [49] Understanding flow chemistry for the production of active pharmaceutical ingredients
    Burange, Anand S.
    Osman, Sameh M.
    Luque, Rafael
    ISCIENCE, 2022, 25 (03)
  • [50] Triboelectrification of active pharmaceutical ingredients: week acids and their salts
    Fujinuma, Kenta
    Ishii, Yuji
    Yashihashi, Yasuo
    Yonemochi, Estuo
    Sugano, Kiyohiko
    Tarada, Katsuhide
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2015, 493 (1-2) : 434 - 438